Physician profile
Stephen H Orr
NPI 1326048851
$7,439.31
in general payments reported to CMS, 2019-2025
28 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,402 · 2020: $658 · 2021: $1,332 · 2022: $527 · 2023: $514 · 2024: $777 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.10 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,927.34 | 2019-2024 | Tecnis Simplicity, Tecnis Iol |
| Ivantis, INC | $1,155.24 | 2019-2021 | |
| Alcon Vision LLC | $929.49 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $746.86 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $401.01 | 2023-2025 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $392.80 | 2019-2022 | |
| Biotissue Holdings INC. | $363.40 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $270.27 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $242.89 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $239.95 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $144.54 | 2019-2025 | |
| Harrow Eye, LLC | $119.68 | 2024-2025 | Iheezo, Vevye, Triesence |
| New World Medical,INC. | $85.42 | 2019-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Amgen INC. | $49.38 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $47.85 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $46.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Kala Pharmaceuticals, INC. | $39.19 | 2019-2021 | |
| Dompe US, INC. | $37.97 | 2024 | Oxervate |
| Ani Pharmaceuticals, INC. | $33.11 | 2025 | Purified Cortrophin Gel |
| Omeros Corporation | $32.53 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $23.91 | 2024 | Syfovre |
| Oyster Point Pharma, INC. | $21.84 | 2022 | |
| Thea Pharma INC. | $18.78 | 2025 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $16.75 | 2025 | Rayone Spheric, Rayone Emv, Rayner Cataract Set 1 |
| Horizon Therapeutics Plc | $16.09 | 2023 | Tepezza |
| Shire North American Group INC | $13.70 | 2019 | |
| Lombart Brothers, INC. | $11.83 | 2019 | |
| Carl Zeiss Meditec, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Orr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.